SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

ARGX-118

ARGX·ARGENX SE
NEUTRAL
Drug Impact Rating1/10
Trial phase
Unknown, not found in any clinical trial registry or pipeline disclosure.
Time to market
Unknown, ARGX-118 cannot be identified in any public source. If it was a preclinical program, it would be years from potential approval, if pursued at all.
Why 1/10
No catalyst is identifiable for ARGX-118 because the drug candidate does not appear in any public database, clinical trial registry, SEC filing, or press release. Without a known development stage or upcoming readout, the impact score defaults to the lowest tier.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

ARGX-118 could not be identified in any available public database or internal source. Investors should verify the correct drug code, argenx's known pipeline includes ARGX-117 (complement inhibitor, Phase 2 completed), ARGX-119 (ALS, Phase 2 terminated), and approved VYVGART/efgartigimod. If ARGX-118 is a preclinical or discontinued program, it has no near-term catalyst value.

Price Chart

Loading chart...

Executive Summary

ARGX-118 is a drug code that could not be identified in any available public database, clinical trial registry, SEC filing, press release, or internal SecBot data source. argenx SE (Nasdaq: ARGX) is a well-established immunology company with approved drug VYVGART (efgartigimod) and known pipeline candidates ARGX-117 (complement inhibitor, Phase 2 completed) and ARGX-119 (ALS, Phase 2 terminated), but ARGX-118 is absent from all records. It may be a preclinical program that was discontinued, renamed, or never publicly disclosed.

How It Works

Unknown. ARGX-118's mechanism of action cannot be determined from any available source. argenx specializes in antibody-based therapies for autoimmune diseases, with its core platform targeting the FcRn receptor (efgartigimod/VYVGART) and complement system (ARGX-117/empasiprubart). ARGX-118 may have been an early-stage discovery program in a similar immunology area, but no public information confirms this.

Trial Status

No clinical trial data available. ARGX-118 does not appear on ClinicalTrials.gov or in any argenx pipeline disclosure accessible through available databases.

The Two-Sided Case

▲ Bull Case3
argenx SE (ARGX) is a well-capitalized biotech with a ~$874 stock price, strong analyst consensus (23 Buy/Strong Buy vs 3 Hold), and a mean price target of ~$1,149 implying ~29% upside.
argenx's approved drug VYVGART (efgartigimod) is generating substantial revenue ($1.5B in Q2 2026 alone), funding a deep pipeline of immunology assets.
If ARGX-118 is an early-stage undisclosed program, it could represent a novel target in argenx's immunology franchise, but no public information exists to evaluate this.
▼ Bear Case2
ARGX-118 is not found in any clinical trial registry, SEC filing, press release, or pipeline disclosure, it may be a discontinued, renamed, or never-publicly-disclosed program.
If ARGX-118 was a preclinical program that was terminated before entering the clinic, it has zero near-term value for investors.

Upcoming Catalysts

  • None identifiable for ARGX-118. For argenx broadly: upcoming Phase 3 myositis readout for efgartigimod (completed July 2026, results pending), Phase 3 multifocal motor neuropathy readout for empasiprubart (primary completion Sept 2026).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARGENX SE 6-K ARGX ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov